RT Journal Article
T1 Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles.
A1 Cabeza, Laura
A1 Ortiz, Raúl
A1 Arias, José L
A1 Prados, Jose
A1 Ruiz Martínez, Maria Adolfina
A1 Entrena, José M
A1 Luque, Raquel
A1 Melguizo, Consolación
K1 Biodegradable polymer
K1 Carcinoma
K1 Cytotoxicity
K1 Chemotherapeutic drug
K1 Drug delivery
K1 Nanopolymer
K1 Adsorción
K1 Animales
K1 Neoplasias de la mama
K1 Línea celular tumoral
K1 Cianoacrilatos
K1 Preparaciones de acción retardada
K1 Doxorrubicina
K1 Enbucrilato
K1 Humanos
K1 Concentración 50 inhibidora
K1 Ratones consanguíneos C57BL
K1 Nanopartículas
AB The use of doxorubicin (DOX), one of the most effective antitumor molecules in the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles (PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing a reduction of the effective dose required for antitumor activity and consequently the level of associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC50) of DOX-loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great potential for improving the efficacy of DOX therapy against advanced breast cancers.
PB Dove Medical Press
SN 1176-9114
YR 2015
FD 2015-02-13
LK http://hdl.handle.net/10668/2099
UL http://hdl.handle.net/10668/2099
LA en
NO Cabeza L, Ortiz R, Arias JL, Prados J, Ruiz Martínez MA, Entrena JM, et al. Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles. Int J Nanomedicine. 2015; 10:1291-306
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 11, 2025